BioNTech Lung Cancer Drug Nearly Doubles Survival vs Chemotherapy in Phase 3 Trial
Gotistobart cut the risk of death by 44% versus docetaxel in metastatic squamous lung cancer, delivering 18.5 vs 10.0 months median survival.
Summary
A new immunotherapy drug called gotistobart, developed by BioNTech and OncoC4, has shown striking survival benefits in patients with previously treated metastatic squamous non-small cell lung cancer. In the first stage of the PRESERVE-003 Phase 3 trial, patients on gotistobart lived a median of 18.5 months compared to just 10.0 months for those on standard chemotherapy docetaxel. That translates to a hazard ratio of 0.56, meaning the drug cut the risk of death by roughly 44%. The safety profile was comparable to docetaxel, with serious adverse events in around 44% of gotistobart patients versus 49% on chemotherapy. These results were presented at the IASLC World Conference on Lung Cancer, with the larger pivotal stage 2 still enrolling.
Detailed Summary
Lung cancer remains one of the leading causes of cancer death worldwide, and late-stage squamous non-small cell lung cancer that has already been treated once carries a particularly poor prognosis. New therapeutic options that meaningfully extend survival in this population represent a significant advance in oncology.
In updated results from stage 1 of the PRESERVE-003 Phase 3 trial, the investigational anti-CTLA-4 antibody gotistobart — co-developed by BioNTech and OncoC4 — achieved a median overall survival of 18.5 months in previously treated metastatic squamous non-small cell lung cancer patients. This compares to 10.0 months for patients receiving the established chemotherapy agent docetaxel. The hazard ratio of 0.56 with a nominal p-value of 0.0295 signals a statistically meaningful and clinically substantial reduction in mortality risk.
The data cut-off was July 17, 2026, at which point median follow-up stood at 25.4 months. A total of 87 patients had been randomized — 45 to gotistobart and 42 to docetaxel — making this a relatively small but informative cohort for a phase 3 stage 1 readout. Safety results were broadly comparable between arms: grade 3 or higher treatment-related adverse events occurred in 44.4% of gotistobart recipients versus 48.8% on docetaxel, suggesting no meaningful worsening of tolerability with the novel agent.
Results were presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer, a leading forum for oncology science. The pivotal stage 2 of the same trial continues to enroll at over 160 sites globally, meaning a definitive efficacy read is still forthcoming.
For longevity-focused readers, extending high-quality survival in one of cancer's most lethal presentations matters enormously. While stage 1 data are non-pivotal and the sample size is limited, the survival signal here is substantial enough to warrant close attention as stage 2 results emerge.
Key Findings
- Gotistobart delivered 18.5 months median overall survival vs 10.0 months for docetaxel in metastatic squamous NSCLC.
- Hazard ratio of 0.56 means gotistobart cut the risk of death by roughly 44% compared to standard chemotherapy.
- Serious adverse events were slightly lower on gotistobart (44.4%) than docetaxel (48.8%), suggesting manageable safety.
- Data come from a non-pivotal stage 1 with 87 patients; the larger pivotal stage 2 is still enrolling at 160+ sites.
- Findings were presented at the IASLC World Conference on Lung Cancer in September 2026.
Methodology
This is a news report summarizing interim results from stage 1 of the PRESERVE-003 Phase 3 randomized controlled trial. The source, Longevity.Technology, is a credible science-focused publication. Data were company-reported and presented at a major oncology conference; peer-reviewed publication has not yet been confirmed.
Study Limitations
Stage 1 enrolled only 87 patients, limiting statistical power and generalizability. The p-value is nominal and the findings are non-pivotal pending stage 2 results. Data are company-reported and not yet peer-reviewed; independent verification is essential before drawing firm conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: